Quick Answer
ArriVent BioPharma, Inc. reported Shares Outstanding of 42.45 million shares for fiscal year 2025.
ArriVent BioPharma, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 42.45M | +25.9% |
| 2024 | 33.71M | +1127.7% |
| 2023 | 2.75M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 40.85M | +21.2% | +9.0% |
| June 30, 2025 | 37.49M | +11.9% | +10.1% |
| March 31, 2025 | 34.04M | +1.6% | +1.0% |
| December 31, 2024 | 33.71M | +1127.7% | +0.0% |
| September 30, 2024 | 33.69M | — | +0.6% |
| June 30, 2024 | 33.51M | — | +0.0% |
| March 31, 2024 | 33.49M | — | +1120.0% |
| December 31, 2023 | 2.75M | — | — |
- ArriVent BioPharma, Inc. showed an increase of +25.9% in Shares Outstanding compared to the prior fiscal year.
- Over the 2023–2025 period, ArriVent BioPharma, Inc.’s shares outstanding has grown by 1446.3% (from 2.75 million shares to 42.45 million shares).
- The most recent figure is from ArriVent BioPharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: